⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
cGAS-Targeting Therapeutics (siRNA / Interface Peptides)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-14 — MA-5 attenuates disease-associated transcriptomic aging and pathological microglial states in Gaucher disease.: cross-connection with mitochonic-acid-5: MA-5 acts upstream of cGAS by preventing mtDNA leakage, converging on the same cGAS–STING axis that direct cGAS inhibitors target — two mechanistically distinct routes to dampening mtDNA-driven sterile inflammation. (novelty: 3)
- 2026-05-15 — Jintiange ameliorates age-related sarcopenia by inhibiting the cGAS-STING signaling pathway via maintaining mitochondrial homeostasis.: cross-connection with jintiange: Both entries act upstream/at the cGAS–STING axis; Jintiange offers a compound-level, mitochondria-preserving route to reducing cytosolic mtDNA sensing. (novelty: 3)
- 2026-09-01 — NADMetabolic Reprogramming Drives CD8T Cells Senescence and Exacerbates Ulcerative Colitis.: cross-connection with nad-precursors: NAD metabolic dysregulation upstream of mtDNA leakage feeds cGAS activation in senescent CD8 T cells, connecting NAD repletion to the cGAS-targeting axis in ulcerative colitis pathogenesis. (novelty: 3)
- 2026-06-27 — Co-exposure to environmental lead and hypertension exacerbates anxiety and depression via mtDNA-mediated cGAS phase separation.: cross-connection with senolytics: Pb+hypertension mouse model implicates mtDNA-mediated cGAS phase separation as the upstream driver of astrocyte senescence that D+Q senolytics rescue, positioning direct cGAS inhibition and downstream senolytic clearance as complementary levers on the same axis. (novelty: 3)
- 2026-07-16 — Age-associated decline of Lamtor5 drives immunosenescence and systemic aging via cGAS-mediated paracrine inflammation.: Aged-mouse mechanistic study: age-related Lamtor5 decline impairs ESCRT-mediated cGAS degradation in macrophages, driving cGAS accumulation and paracrine SASP-like inflammation; macrophage-targeted cGAS siRNA and a Lamtor5/cGAS interface-disrupting peptide alleviated systemic aging phenotypes — provides the founding preclinical rationale for macrophage-restricted cGAS blockade as an anti-immunosenescence strategy. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Age-associated decline of Lamtor5 drives immunosenescence and systemic aging via cGAS-mediated paracrine inflammation.
16-jul-2026
novelty 3
per-area 3
strengthens